MYC is frequently overexpressed in human cancers, but the downstream events contributing to tumorigenesis remain incompletely understood. MYC encodes an oncogenic transcription factor, of which target genes presumably contribute to cellular transformation. Although Myc regulates about 15% of genes and combinations of target genes are likely required for tumorigenesis, we studied in depth the expression of the Myc target gene, JPO1/CDCA7, in human cancers and its ability to provoke tumorigenesis in transgenic mice. JPO1/CDCA7 is frequently overexpressed in human cancers, and in particular, its expression is highly elevated in chronic myelogenous leukemia blast crisis as compared with the chronic phase. In murine lymphoid tissues, ectopic human JPO1/CDCA7 expression resulted in a 2-fold increased risk of lymphoid malignancies at 1 year. The transgene, which was driven by the H2-K promoter, exhibited leaky expression in nonlymphoid tissues such as kidney. We observed a significant increased incidence of transgenic animal solid tumors, which were not seen in littermate controls. These observations suggest that JPO1/ CDCA7 may contribute to Myc-mediated tumorigenesis. 
Introduction
In addition to the chromosomal translocations, which are hallmarks of Burkitt's lymphoma (1) (2) (3) (4) , involving MYC, its expression is frequently increased in many different tumor types including breast, colon, lung, and prostate ( for a compilation of 93 studies see http://www.myc-cancer-gene.org; refs. [5] [6] [7] . In contrast to normal MYC, which displays tightly regulated expression, deregulated MYC in cancer cells may contribute to the process of transformation by altering the expression of a set of target genes regulated by the c-Myc transcription factor (8, 9) . These targets affect a variety of functions including control of cell growth and apoptosis, as well as cellular metabolism, adhesion, and differentiation (6, (10) (11) (12) . Extensive studies have identified thousands of Myc target genes that may cooperate to promote tumorigenesis (http://www.myc-cancer-gene.org; ref. 7) . The current challenge is to identify those critical target genes that play significant roles in human cancers, as well as in Myc-mediated tumorigenesis in experimental models.
Although the Myc target gene network involves about 3,000 human genes, which participate in cell cycle regulation, glucose metabolism, ribosome biogenesis as well as other cellular processes, how deregulated MYC expression contributes to tumorigenesis through targets genes remains poorly understood. In particular, the contributions of large numbers of target genes with unknown functions to Myc-mediated tumorigenesis remain undelineated. Here, we sought to determine the expression pattern of JPO1/CDCA7, which encodes a nuclear protein with unknown function, in human cancers and its transforming activity in transgenic mice.
We identified JPO1 as a novel transcript that is differentially regulated in Myc-transformed fibroblasts in a representational difference analysis screen (13) . The gene has since been officially termed CDCA7 by the Human Genome Nomenclature Committee based on its periodic expression in the cell cycle, peaking at the G 1 to S phase transition (14) . JPO1/CDCA7 is encoded by a nine-exon gene located at 2q31 that produces a 2.5 kb transcript expressed in the adult thymus and small intestine and an alternatively spliced transcript. Our previous work confirmed JPO1/CDCA7 as a direct Myc target through the use of an inducible Myc system, and showed that its expression is strongly correlated with Myc in experimental systems that have been examined, including human Burkitt's lymphoma cell lines (15) . Moreover, chromatin immunoprecipitation assays verified that Myc directly binds the JPO1/ CDCA7 genomic locus (16) .
The 47 kDa JPO1 protein encoded by JPO1/CDCA7 consists of 371 amino acids and is localized to the nucleus (15) . JPO1 contains two putative functional domains: a leucine zipper motif in the NH 2 -terminal region of the protein and a cysteine-rich region that is homologous to a class of DNA-binding proteins in plants (Fig. 1A) . JPO1/CDCA7 is conserved across species and has orthologues in mouse, rat, and Xenopus, among others. Early experiments by Prescott et al. (15) showed that overexpression of JPO1/CDCA7 in rat fibroblasts conferred some transforming properties, although the ability of JPO1/CDCA7 to induce colony formation in soft agar assays was diminished and variable compared with Myc. Although the same JPO1-overexpressing cells were unable to form tumors when injected into nude mice, JPO1/CDCA7 complemented the hypomorphic W135E mutant MYC allele in transforming Rat1a cells (15) .
Given its remarkable increased expression in Myc-transformed cells and the in vitro complementation of JPO1 with a weak mutant MYC allele in transformation, we sought to determine the potential role in vivo of JPO1/CDCA7 in human cancers by assessing its expression levels in primary samples and its transforming potential in the T-cell and B-cell compartments in a transgenic mouse model. We measured JPO1/CDCA7 expression in human tumors and found that its expression is elevated in a significant fraction of human colon, rectum, ovary, lung, uterus, and stomach cancers. Its expression is also highly elevated in acute myelogenous leukemia and, in particular, in chronic myelogenous leukemia (CML) blast crisis as compared with chronic phase CML. The tumorigenic role of JPO1/CDCA7 is further supported by a 2-fold increase risk of developing lymphoid malignancies and, surprisingly, a dramatic increase in solid tumors in transgenic mice ectopically expressing JPO1/CDCA7 in T and B cells.
Materials and Methods
Multiple tumor array hybridization and quantitation. Multiple tumor and blood disease arrays were obtained from Clontech/BD Bioscience (Mountain View, CA) and hybridized using cDNA probes to JPO1/CDCA7, c-Myc, and ubiquitin. Probes were random primed, labeled (Stratagene, La Jolla, CA) with [a-32 P]dATP, and 3 Â 10 6 cpm/mL of hybridization solution (ExpressHyb, Clontech, Mountain View, CA) were added to the arrays and hybridized overnight. Arrays were washed according to the recommendations of the manufacturer and exposed overnight to a phosphorimager screen, followed by quantitation using ImageQuant software.
Real-time analysis on patient tumor samples. Samples of WBC were obtained from patients with CML or acute myelogenous leukemia (AML) and RNA was extracted using the RNeasy method (Qiagen, Valencia, CA).
Real-time PCR primers and a Fam-labeled probe (Applied Biosystems, Foster City, CA) were designed to detect the human sequence of JPO1/ CDCA7 at the junction of exons 7 and 8. Probes for MYC were commercially available (Applied Biosystems). Transgenic RNA was amplified in a one-step reverse transcription-PCR (RT-PCR) reaction (Applied Biosystems). Expression was normalized to human h-actin (Applied Biosystems). Studies on deidentified patient tumor samples obtained from University of California at Los Angeles, Hopkins, and University of Maryland Medical Center were approved by the Johns Hopkins Medicine Institutional Review Board.
Creation of transgenic mice and breeding. A transgene construct was created by cloning the coding sequence of JPO1 (Hs.470654) into the SalI sites of the vector pHSE3V (a gift of S. Desiderio, Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD; ref. 17). The resulting plasmid was then linearized using XhoI to create a fragment of DNA containing the JPO1 coding sequence, along with the H2-K promoter, exons 2 and 3 of the h-globin gene, and the immunoglobulin A heavy chain enhancer. This fragment was then injected into fertilized eggs from C57Bl6 or B6SJL female mice (transgenic core) and maintained by crossing hemizygous mice to wild-type C57Bl6 mice. Presence of the transgene was assessed by PCR using one primer in the H2-K sequence and another in the coding sequence of JPO1. Initial litters were confirmed using Southern blot analysis.
Analysis of transgene expression by real-time PCR. Following autopsy, sections of spleen and thymus were frozen in liquid nitrogen, crushed, and homogenized. RNA was extracted using the TRIzol method (Invitrogen). Real-time PCR was carried out as described above. RNA expression was normalized to mouse 18S (Applied Biosystems).
Immunohistochemistry. During necropsy, all organs were removed, preserved in formalin, and then embedded in paraffin blocks. Five-micron unstained sections were cut onto polylysine slides which were then deparaffinized in xylene for 30 minutes, followed by ethanol hydration and washes in PBS. The slides were boiled in antigen unmasking solution (Vector Laboratories, Burlingame, CA) for 10 minutes, and left in the solution at room temperature for an additional 20 minutes. Following two more PBS washes, slides were quenched in 0.6% hydrogen peroxide/ methanol, washed again in PBS, and then blocked overnight in a humidifying chamber at 4jC using normal blocking serum (Vector Laboratories, VectaStain Elite ABC kit). After washing in PBS thrice, slides were incubated with either primary antibodies to JPO1 (15) or rabbit immunoglobulin G (IgG; Vector Laboratories) for at least 1 hour. Following another three PBS washes, slides were incubated with secondary antibody for 30 minutes to 1 hour and then detected with the VectaStain Elite ABC reagents and counterstained with hemotoxylin (Vector Laboratories).
Analysis of phenotype. Transgenic mice and normal littermates were sacrificed by CO 2 asphyxiation and necropsy was done. Mouse tissue was preserved in formalin following necropsy, paraffin embedded, and H&E stained. Slides were prepared and then evaluated for neoplastic phenotype without knowledge of transgene status.
Results
Expression of JPO1/CDCA7 and MYC in solid tumors. Overexpression of Myc and its target genes is a frequent event in human cancers. As a first approximation, we sought to determine whether JPO1/CDCA7 participates in human tumorigenesis by assessing the level of its expression in human malignancies. To Figure 2 . A, blood disease profiling array probed for JPO1/CDCA7 . Each horizontal row represents cDNA from six cell fractions derived from a single patient, as indicated by the box in the AML section. Each vertical column represents samples for a given fraction as indicated by a letter below each column. The disease is indicated above each section. HD, Hodgkin's disease; LN, normal lymph nodes; vWD, von Willebrand's disease; NHL, non-Hodgkin's lymphoma. The blood fractions are as follows: a, CD14 (monocyte/macrophage); b, CD19 (B cell); c, CD3 (T cell); d, mononuclear cells; e, polymorphonuclear; f, total leukocyte; g, lymph node. B, blood disease profiling array probed for MYC. The array is identical to the one used in A. C -E, quantitation of CDCA7/JPO1 and MYC expression in hematologic malignancies. For each disease, the sorted fractions most likely to contain the neoplastic cells were analyzed. Note that the percent of patients with a greater than 2-fold disease to normal ratio based on array quantification is plotted for each fraction. The array included 12 patients with AML (A), 7 with CML (B ), and 9 with non-Hodgkin's lymphoma (C ). F, expression of JPO1/CDCA7 and MYC in the individual CML patient samples. Y axis, normalized signal for JPO1/ CDCA7 and MYC in each patient's mononuclear sample, divided by the averaged signal detected in normal monocytes. determine the expression of JPO1/CDCA7 in a large number of human tumors, we used filter arrays that have been quantitatively spotted with cDNAs to reflect the original mRNA levels in a number of different types of solid tumors (Fig. 1B and C) . Arrays were probed with random-primed, radiolabeled JPO1/CDCA7 or MYC cDNAs and quantitated by a phosphorimager. All values were normalized to ubiquitin according to instructions of the manufacturer and represent the average of two independent hybridizations on separate arrays. To obtain values for the relative expression of JPO1/CDCA7 and MYC in tumor tissue compared with normal tissue, the value for each tumor spot on the array was compared with the matched normal tissue provided from the same individual. Tumors that showed a greater than 2-fold tumor to normal ratio were considered to overexpress JPO1/CDCA7. Figure 1D shows a graphical representation of the percentage of solid tumors overexpressing JPO1/CDCA7 and MYC.
Expression of JPO1/CDCA7 and MYC in hematologic malignancies. To determine the expression of JPO1/CDCA7 in human hematologic malignancies, we probed an array (Clontech) similar to the multiple human cancer array, which allows for the analysis of multiple blood fractions from patients with no disease (designated as normal), AML, Hodgkin's disease, von Willebrand's disease, CML, or non-Hodgkin's lymphoma. Seven normal lymph node samples were also included. Blots were probed for both JPO1/CDCA7 and MYC ( Fig. 2A and B) . For the hematologic malignancies, normal samples from patients are unavailable, and hence the values for each sample were compared with the corresponding averaged values from the normal donors spotted in the top left of the array.
For each type of hematologic malignancy, except nonHodgkin's lymphoma and Hodgkin's disease, we looked specifically at the expressions of JPO1/CDCA7 in the fractions that are likely to contain the malignant cells for each disease. Data are shown for AML, CML, and non-Hodgkin's B-cell lymphoma in Fig. 2C to E. Because JPO1/CDCA7 is normally expressed in T lymphocytes, it is surprising that JPO1/CDCA7 and MYC are most consistently up-regulated in AML patients, and not those with lymphomas. It should be noted, however, that the blood fractions are less likely to reveal neoplastic cells in the case of lymphomas. The one lymph node available (second case down from the top of Among the CML patient samples, it is remarkable that patients in the acute or blast crisis stages of disease (samples 1-4) expressed very high levels of JPO1/CDCA7 in the mononuclear fraction (row d), compared with patients in the chronic phase of disease (samples 5-7). The level of expression of JPO1/CDCA7 and MYC for each individual CML patient is shown in Fig. 2F . To extend these initial observations, samples were obtained from nine patients with AML and 20 patients with CML (9 patients in blast crisis and 11 patients in the chronic phase from three cancer centers). Levels of JPO1/CDCA7 mRNA were analyzed by real-time PCR and a tumor to normal ratio was obtained by comparison to a normal WBC control (Fig. 3) . As expected, AML samples show varying degrees of JPO1/CDCA7 overexpression. In the CML samples, although the level of JPO1/CDCA7 expression varies widely and overlaps between blast crisis and chronic phase patients, there is a statistically significant higher JPO1/CDCA7 expression in the blast crisis samples as compared with chronic phase. Comparison of blast versus chronic CML patients using a t test (two tailed, type 3) gave a P value of 0.038; for chronic versus AML (two tailed, type 2 t test) P = 0.012; and for AML versus blast (two tailed, type 2 t test) P = 0.318. A P value of <0.05 was considered significant. JPO1/CDCA7 transgenic mice. Given that we previously found JPO1/CDCA7 transforming activity in vitro and that its expression is elevated in a number of human cancers in this study, we sought to determine the potential transforming activity of JPO1/CDCA7 in vivo in transgenic mice. We began these studies knowing that JPO1/CDCA7 is expressed in the thymus and small intestine, and that it is overexpressed in a number of human Burkitt's lymphoma cell lines. As such, we chose to target the murine lymphoid compartment by expressing human JPO1/CDCA7 in transgenic mice under the control of the murine promoter H2-K and EA enhancer (Fig. 4A ). This expression vector has been successfully used to express N-myc and BAP130/TFII-I in transgenic T and B lymphocytes (18) . An alternatively spliced form JPO1/CDCA7 was not known at the time we constructed the mice and, hence, the shorter spliced form of the human JPO1/CDCA7 coding sequence was used.
Four transgenic lines were created, and the presence of the transgene was confirmed by PCR analysis of DNA extracted from tail clippings (Fig. 4B) . From the original four founders, two lines of transgenic mice were successfully established; one on the C57Bl6 background and the other on the B6SJL hybrid background. B6SJL founders were bred against C57Bl6 for at least five generations. To determine the expression pattern of the transgene, RNA was extracted from various organs and analyzed by real-time PCR for several mice derived from each of the two founders from which we were able to propagate lines. Figure 5A shows representative expression data for two of the mice. As expected, expression of the transgene is high in both the T-and B-cell compartments. A common incidental finding in these animals was cystic kidneys, leading us to examine the expression of the transgene in the kidney (Fig. 5A ). Because littermates with and without the transgene developed cystic kidneys, which seem to be secondary to hydronephrosis, at equal frequency, it is not likely that leaky expression of the transgene could cause this phenotype. Expression of the transgene in lymphoid tissues at the protein level was confirmed by immunohistochemical staining using polyclonal antibodies raised against JPO1. Figure 5B shows a representative transgenic spleen section that stained positively with antihuman JPO1 as compared with one that did not stain with an isotype control IgG. Sections from nontransgenic littermates were also stained with anti-JPO1 antibody and IgG, and these were both negative (data not shown).
Although young JPO1 transgenic mice appeared normal and healthy and early sacrifices of JPO1 transgenic animals showed no abnormalities, one founder at 8 months developed a gait disorder that rapidly progressed to hind limb paralysis. This animal could not be propagated and was found to have a lymphoma that infiltrated the thoracic spine. The animals were therefore allowed to attain 1 year of age before sacrifice, at which time they were necropsied and analyzed for evidence of neoplasia. Table 1 lists the phenotypes that were observed in the 1-year-old animals. The types of tumors observed and the rates at which they occurred are shown in Fig. 6A . A total of 45 animals that contained the JPO1 transgene (a combination of the four founder lines with two that were able to be propagated) were analyzed and compared with 28 nontransgenic age-matched littermates. In addition to an increased incidence of lymphomas (see representative tumor histology, Fig. 6B ), other types of solid tumors also intriguingly significantly increased in frequency. In fact, no solid tumors were observed in littermate controls. Because this effect was specific to the presence of the transgene, and we have shown that the transgene is expressed in the kidneys of transgenic animals, it is possible that there is some level of JPO1/CDCA7 expression due to the H2-K promoter in the tissues from which the tumors arose. To confirm expression of the JPO1/CDCA7 transgene in the tumors, sections were stained with anti-JPO1 antibodies. Specific staining was observed in both a pancreatic lymphoma and a splenic histiocytic sarcoma (Fig. 7) . Statistical analysis using binomial sampling revealed a trend for increased tumorigenesis in JPO1/CDCA7 transgenic mice; however, significance was not reached with a twosided P value of 0.296, Z score = À1.045. Figure 6 . A, the rate of tumor formation in 1-year-old JPO1/CDCA7 transgenic mice as compared with nontransgenic, age-matched littermates. Data are compiled from all four founders. Tumors observed for nontransgenic animals were pancreatic lymphoma (n = 1) and mesenteric lymphoma (n = 2); for transgenic animals: pancreatic lymphoma (n = 2), thymic lymphoma (n = 1), mesenteric lymphoma (n = 1), histiocytic sarcoma (n = 2), intestinal adenocarcinoma (n = 2), stomach papilloma (n = 1), and bronchoalveolar adenoma (n = 1). Note that one transgenic mouse had both a pancreatic and a mesenteric lymphoma, which were combined as one for determination of incidence. B, representative histology from necropsy of JPO1/CDCA7 transgenic mice. Left, a lymphoma in pancreatic lymph node. Black arrows, mitoses; white arrows, prominent nucleoli; arrowhead, vesicular nucleus. Right, histiocytic sarcoma present in spleen. Black arrows, giant cells on a background of histiocytes; white arrow, mitosis.
Myc Target JPO1/CDCA7 in Human Cancers 
Discussion
Although the molecular function of the JPO1 nuclear protein remains largely unknown, the fact that it is a direct Myc target that is highly up-regulated when cells grow independently of anchorage suggests that it may play an important role in tumorigenesis (13, 15) . When the amino acid sequence of JPO1 is compared via National Center for Biotechnology Information BLAST search to other proteins, several functional domains are recognized, including a leucine zipper motif and a cysteine-rich region that is present in plant DNA-binding proteins. The presence of these functional domains suggests that JPO1 either homo-oligomerizes or may have an unknown binding partner that would allow it to bind DNA and perhaps modulate transcription.
Until recently, there were no human proteins in the database that showed significant homology to JPO1. A recent sequence entry (EAL24271; Locuslink 55536), termed transcription factor RAM2 or JPO2 (19) , which shows high homology to JPO1 in both the leucine zipper and cysteine-rich region, has been identified as a transcription factor that modulates genomic integration of adenoassociated virus (as annotated in Genbank entry AY161169). 7 Whereas we observed that JPO1 does not associate with JPO2 by coimmunoprecipitation, 8 both proteins can interact with the Myc NH 2 -terminal domain (19) . In addition to the finding that JPO2 is transforming in medulloblastoma cells (19) , we also found that JPO2 can induce colony formation in soft agar when overexpressed in Rat1a fibroblasts, whereas JPO1 displays a weaker transforming phenotype. 9 Moreover, JPO2 is able to transform human medulloblastoma cells and collaborates with a mutant Myc (W135E), as does JPO1 (15), to transform Rat1a cells (19) . The observation that JPO1 could bind the Myc transactivation domain (19) suggests a possible positive feed-forward loop, such that Myc transactivates JPO1, which in turn collaborates with Myc in transformation. These observations on JPO2, taken together with our observations that JPO1 has limited transforming activity, suggest that these structurally related proteins could contribute to tumorigenesis.
To begin to understand the potential role of JPO1/CDCA7 in human cancers, we measured the expression of MYC and JPO1/ CDCA7 in human malignancies simply to determine whether they are concordantly overexpressed as compared with normal tissues. Although both MYC and JPO1/CDCA7 are frequently overexpressed in human malignancies, their magnitudes of induction are not always concordant. For example, whereas the expressions of MYC and JPO1/CDCA7 are concordant in colorectal carcinomas, only JPO1/CDCA7 is overexpressed in lung cancers. These observations suggest that whereas high MYC may be sufficient to induce JPO1/CDCA7 expression, MYC is not necessary and other oncogenic events may induce JPO1/CDCA7 independently of MYC. A similar phenomenon has been observed with the Myc target gene HMG I/Y in breast cancer cell lines. A comparison of HMG I/Y and Myc levels in multiple breast cancer lines revealed that those cell lines with the highest levels of the target gene (HMG I/Y) are not necessarily correlated with the highest levels of Myc (20) .
JPO1/CDCA7 is not only overexpressed in solid tumors but is also strikingly overexpressed in myeloid leukemias. Intriguingly, the expression pattern of JPO1/CDCA7 on the human hematologic malignancies array shows an elevation of JPO1/CDCA7 expression in both acute and chronic myelogenous leukemia. Increased expression of MYC has been previously observed in CML patients (21) . Trisomy 8 and amplification of the MYC locus on chromosome 8 are also observed in CML (22) . In addition, the Bcr-Abl oncogenic fusion protein, a hallmark of CML, has been shown to increase MYC expression and increase Myc protein stability through interaction with Jak2 (23). Expression of Myc was also shown to be essential for transformation by Bcr-Abl (24) . These data in aggregate imply that downstream targets of Myc may play a role in mediating the growth phenotype observed in CML. The fact that JPO1/CDCA7 is highly expressed in the blast or terminal phases of CML, but not in the chronic phase, suggests that JPO1/CDCA7 could be a marker for disease progression. Microarray analysis experiments that compare gene expression profiles in blast versus chronic phase samples have failed to identify a common set of genes that are specifically expressed in Figure 7 . Immunohistochemistry for JPO1/CDCA7 in transgenic mouse tumors. Pancreatic lymphoma stained with JPO1 antibodies (left) and IgG isotype control (right ); Â200. Histiocytic sarcoma from spleen stained with antibodies against JPO1 (left ) and IgG isotype control (right ); Â200. Normal spleen from nontransgenic mouse stained with JPO1 antibodies as a negative control; Â200.
all samples in a given phase (25) . Instead those studies suggest that whereas the expression pattern changes with disease progression, CML is a heterogeneous disease and there are no specific changes that can be used to monitor the transition from chronic to blast phase (25) . The overlap in JPO1/CDCA7 expression levels between chronic and terminal phase leukemia could reflect this phenomenon.
Both our previous in vitro study of cell lines (15) and our current study of JPO1/CDCA7 expression in human cancers support the notion that JPO1/CDCA7 contributes to tumorigenesis. To further establish the role of JPO1/CDCA7 in tumorigenesis, we constructed transgenic mice in which JPO1/CDCA7 is overexpressed in T and B lymphocytes. Studies of the transgenic mice suggest that JPO1/ CDCA7 has a mild tumorigenic effect in vivo. The lag time required for tumor formation indicates that there are multiple hits that must be acquired for tumorigenesis to take place. This is not unexpected, and is also seen in the EA-myc transgenic mouse model, where mice expressing c-Myc under the control of an immunoglobulin enhancer element develop lymphomas and lymphoblastic leukemias with a lag time of 3 to 6 months. The tumors that develop in that mouse model are clonal, suggesting that additional genetic lesions are necessary to initiate tumor formation even in the presence of high levels of Myc (26, 27) . The observation that other solid tumors can also be induced in the JPO1/CDCA7 transgenic mice suggests that the H2-K promoter construct with an EA enhancer is leaky. These observations are compatible with the finding that JPO1/CDCA7 may be dysregulated in various types of human malignancies. Indeed, JPO1/CDCA7 is up-regulated in a large percentage of solid tumors derived from colon, rectum, ovary, stomach, uterus, and lung.
In summary, the Myc oncogenic transcription factor contributes to tumorigenesis through regulation of thousands of genes with many novel ones of which functions are unknown. Among these, we identified JPO1/CDCA7 as one that encodes a nuclear protein JPO1 without a known function, although its high homology with the transcription factor JPO2 or RAM2 suggests that JPO1 is also a transcription factor. To begin to understand the JPO1/CDCA7 gene, we took a multi-pronged approach. In aggregate, our transformation studies with cell lines in vitro, expression analysis of JPO1/CDCA7 in human cancers, and in vivo tumorigenic studies in transgenic mice all support a role for JPO1/CDCA7 in tumorigenesis. As compared with MYC, JPO1/ CDCA7 is weakly transforming in vitro and in vivo; however, the widespread overexpression JPO1/CDCA7 in human cancers suggests a more profound role.
